Swiss intermediates and fine chemical company Lonza said today it
is to cut around 500 jobs mainly in Europe and the US as part of a
restructuring programme to reduce the negative effects of the
current economy on most of its business...
Speciality chemicals company International Specialty Products (ISP)
continues its quest to expand the company's presence in the growing
personal care market segment with the news this week that it has
collaborated with biotech...
Netherlands-based drugs, coatings and chemical maker Akzo Nobel has
announced a €500 million divestment program and suggested that it
is unlikely to remain a player in all three of these sectors in the
UK-based vaccine maker PowderJect is now said to be in the latter
stages of takeover negotiations, with the interested party widely
tipped to be the USA's Chiron, rumoured to be proferring a bid
valuing the company at around...
In the US this week, supplier of botanical extracts for the
pharmaceutical industry Pharmachem Laboratories announced that it
has acquired 'the largest botanical extraction facility in North
America, producing extracts for the...
The launch of newer technology products with a wide range of
applications and the facility to deliver proteins, peptides, and
large molecules is expected to rake in market revenues, according
to a new report from market analysts Frost...
Despite a testing global economic climate, sales remained steady
and earnings before interest and taxes rose for German speciality
chemicals company Degussa in the first quarter of 2003. But guarded
optimism remains for 2003.
Spotlight on the home of the celebrated pork pie in England, with
the annoucement this week that Melton Mowbray-based Bridgehead
Technologies and Pharmalicensing - two biopharmaceutical business
development companies - are to merge.
US manufacturer of vitamins, minerals, herbs and supplements
D&E Pharmaceuticals, has launched a contract manufacturing
services initiative, principally aimed at small to medium sized
US zuChem, a development-stage company that focuses on
commercialising manufacturing processes for glycochemicals, has
raised a considerable chunk of capital. Funds earmarked for
development of new sugar-based pharmaceutical intermediates.